insights_auto
Why is MVIR down 5,56%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
1,46 SEK
arrow_downward
-5,56%(-0,086) 1D
8 ოქტ, 17:29:45 GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
1,54 SEK
High
1,55 SEK
Low
1,45 SEK
Mkt. cap
914,08 მლნ.
Avg. vol.
1,48 მლნ.
Volume
3,06 მლნ.
52-wk high
2,88 SEK
52-wk low
0,34 SEK
EPS
-0,37 SEK
Shares outstanding
624,18 მლნ.
No. of employees
6
Open
1,54 SEK
High
1,55 SEK
Low
1,45 SEK
Mkt. cap
914,08 მლნ.
Avg. vol.
1,48 მლნ.
Volume
3,06 მლნ.
52-wk high
2,88 SEK
52-wk low
0,34 SEK
EPS
-0,37 SEK
Shares outstanding
624,18 მლნ.
No. of employees
6
News stories
From web sources and news partners
Renaissance Capital
·
1 საათის წინ
Metal powder producer Amaero revives Nasdaq listing plans, slashing deal size by about 60% ahead of $20 million IPO
Simply Wall Street
·
37 წუთის წინ
Does AST SpaceMobile (ASTS) Canada Test Change The Direct To Device Story?
Investor's Business Daily
·
1 საათის წინ
Futures: AI Stocks Skid On OpenAI; SpaceX Move Hits Telecom Rivals
Yahoo Finance
·
1 საათის წინ
XLG Cuts the S&P 500 Down to 50 Stocks. The Result Is an Index Fund Built Entirely Around Mega-Caps
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB